Keywords
delirium, dexmedetomidine, acetaminophen, cardiac surgery, coronary artery bypass grafting (CABG), propofol, cognitive assessments
delirium, dexmedetomidine, acetaminophen, cardiac surgery, coronary artery bypass grafting (CABG), propofol, cognitive assessments
Delirium is defined as a change in mental status, characterized by acute onset and fluctuating course, inattention, disorganized thinking, and altered level of consciousness1,2. Delirium increases the risk of mortality, readmissions, and accelerated cognitive decline2–6. Around 158 billion dollars of national healthcare cost is attributable to delirium7. The incidence of delirium in cardiac surgery is 11–46%2. Delirium is preventable in 30–40% of the cases2. Some of the modifiable risk factors for delirium include the choice of analgesic and sedatives8.
Currently used sedatives, like midazolam, act via GABA receptors and release deliriogenic mediators9. Dexmedetomidine is an alpha 2 adrenergic agonist, with no interaction with GABA receptors.
A recent study by Li et al. in 285 elderly cardiac surgical patients evaluated dexmedetomidine versus propofol and showed no difference in the incidence of delirium10. A major limitation of this study is that Confusion Assessment Method (CAM) and CAM- ICU are limited assessments and may miss delirium. There are other tools that could help assess cognitive assessment more efficiently. A meta-analysis suggested that the use of dexmedetomidine for sedation in cardiac surgery patients may reduce the incidence of delirium9. The first study in the meta-analysis was a retrospective study by Corbett SM et al. that does not mention how delirium was assessed in individual hospitals11. The second study by Shehabi Y et al. was not powered adequately and used CAM-ICU for assessing delirium both in intubated and extubated patients which have reduced sensitivity for delirium in verbal patients and could have underestimated the incidence of delirium12. The third study was a small study by Maldonado JR et al. of only 118 patients recruited and only 90 patients finally analyzed, with 28 randomized patients excluded for protocol violations which introduce a significant selection bias13. It also showed a 94% reduction in the incidence of delirium and this effect size is almost implausibly large and has not been seen in other studies. The final study by Dasta JF et al. was not designed to identify patients with delirium with any specific tools such as CAM and thus could have gross underestimated delirium incidence14.
The use of IV acetaminophen (IVA) has been shown in multiple studies to reduce the amount of opioids consumed by patients undergoing surgeries4,15. IVA has never been studied in the context of cardiac surgery and delirium prevention. So, we hypothesized that the use of dexmedetomidine and acetaminophen would provide adequate analgesia, leading to a decreased opioid consumption and decreased incidence of delirium.
This is a pilot trial which ran from 13th November 2013 to 9th April 2015 to assess the feasibility of using IV dexmedetomidine and acetaminophen in the cardiac surgical intensive care unit. The study also aimed to obtain effect size estimates for primary study outcomes which will help power an ongoing large scale randomized trial (NCT02546765, registered on 13th January 2015).
This is a single-centered, double-blinded, prospective, randomized controlled pilot trial.
Patients who are 60 years of age or older who were undergoing coronary artery bypass grafting (CABG), and/or valve surgery were included in the study. Exclusion criteria were preoperative left ventricular ejection fraction < 30%, emergent and percutaneous procedures, aortic surgeries, preexisting cognitive impairment, recent seizures, patients on medications for cognitive decline, serum creatinine > 2 mg%, liver dysfunction, known history of alcohol or drug abuse, and hypersensitivity to any of the study drugs. (Figure 1)
Fourteen patients were recruited (the initial 2 patients to help train the investigators in the use of cognitive assessments). The remaining twelve patients were randomized into the following 4 groups, containing 3 patients each (1:1:1:1 allocation). (Table 1)
Group* | Sedation | Acetaminophen |
---|---|---|
Group 1 (P) | Propofol | No |
Group 2 (P+A) | Propofol | Yes |
Group 3 (D) | Dexmedetomidine | No |
Group 4 (D+A) | Dexmedetomidine | Yes |
Each patient was allotted a randomization number based on which the pharmacist assigned the study medications.
Peri-operative anesthetic management was administered according to standard of care. Intra-operative propofol infusion was administered at the clinician’s discretion for patients in propofol group. In the post-operative period, propofol infusion was titrated to 25–100 µg/kg/min. If the patient was randomized to dexmedetomidine group, propofol infusion was avoided inside the operating room (OR). Dexmedetomidine infusion was given after chest closure at a dose of 0.1–1.0 µg/kg/hr. The medications for sedation were continued in the post-operative period until extubation or for a minimal duration of 6 hours. For patients randomized to IVA group, IVA 1 gram was given every 6 hours for the first 48 hours postoperatively up to a total of eight doses.
Cognitive assessments were conducted using standard battery used for Minimental (MMSE) and Confusion Assessment Method (CAM).
The primary outcome measured was the proportion of patients who completed the protocol successfully, which reflects the feasibility of the study. The incidence of delirium was measured to obtain effect size estimates for future studies. Secondary outcomes included hypotension, duration of delirium, breakthrough analgesic requirements, ICU days, and length of hospital stay.
The baseline characteristics of the patients were comparable in all groups. The total incidence of delirium was 42% (5/12). The incidence of delirium was 67% (2/3) with propofol and 67% (2/3) with dexmedetomidine. Dexmedetomidine+Acetaminophen group had an incidence of 33% (1/3). The Propofol+Acetaminophen group had no occurrence of delirium. Interestingly, only 17% (1/6) of the subjects who received IVA were diagnosed with delirium compared to 67% (4/6) in the group who did not receive IVA. (Table 2) Also, the incidence of delirium was 33% (2/6) in the propofol groups as compared to 50% (3/6) in the dexmedetomidine groups. The mean duration of delirium ranged from 0 to 1 day. (Table 3) Secondary outcomes were similar between the groups. One patient expired after surgery, unrelated to the study protocol. One patient in the dexmedetomidine group experienced a significant hypotension with systolic blood pressure <90 mm of Hg.
Propofol | Dexmedetomidine | Acetaminophen | No Acetaminophen | |
---|---|---|---|---|
Incidence of Delirium % (n/N) | 33.3 (2/6) | 50 (3/6) | 16.7 (1/6) | 66.7 (4/6) |
Mean Delirium duration [n days] | 0.5 | 1 | 0.5 | 1 |
Opioid consumption mean [SD]* | 8.2 [2.02] | 11.46 [4.2] | 7.54 [2.15] | 12.12 [4.06] |
Time to extubation (mins) mean [SD] | 410.67 [320.25] | 439 [239.32] | 499.5 [304.63] | 350.17 [232.66] |
Length of stay (days) mean [SD] | 5.67 [0.82] | 8.5 [6.5] | 7.83 [6.52] | 6.33 [1.97] |
Adverse events | 0 | 1 | 0 | 1 |
Dexmedetomidine dose mean [SD]** | N/A | 0.95 [0.36] | N/A | N/A |
Propofol dose mean [SD]*** | 43.33 [5.16] | N/A | N/A | N/A |
Propofol | Propofol + Acetaminophen | Dexmedetomidine | Dexmedetomidine + Acetaminophen | |
---|---|---|---|---|
Incidence of Delirium % (n/N) | 66.6 (2/3) | 0 (2/3) | 66.6 (2/3) | 33.3 (1/3) |
Mean Delirium duration [n days] | 1 | 0 | 1 | 1 |
Opioid consumption mean [SD]* | 2.84 [1.95] | 2.63 [2.2] | 5.24 [5.3] | 2.4 [2.2] |
Time to extubation (mins) mean [SD] | 213.67 [42.83] | 607.67 [371.66] | 486.67 [278.55] | 391.33 [242.43] |
Length of stay (days) mean [SD] | 6 [0] | 5.33 [1.15] | 6.67 [3.06] | 10.33 [9.29] |
Adverse events | 0 | 0 | 0 | 1 |
The use of IV dexmedetomidine and acetaminophen in the cardiac surgical patients was feasible. The study protocol was easily incorporated into patient care. All the enrolled patients completed the study protocol. There were no instances where the implementation of the study protocol was abandoned by the physicians. Sedation provided was useful. Apart from the incidence of hypotension in one patient with dexmedetomidine use, no other adverse events recorded directly related to the intervention.
No other statistical evaluation was done due to the small sample size. The overall incidence of delirium in our trial, at 42%, is close to previous reports2. The incidence of delirium in patients receiving IVA was 17% compared to 67% in the other group suggesting that IVA may be beneficial in reducing the incidence of delirium following cardiac surgery. The pilot study led to a larger ongoing trial (NCT02546765).
A major limitation of our study is the small sample size, but this was a feasibility trial to study effect size for the design of future larger studies. Also, there was no blinding for the choice of sedatives used in the patients. The assessors were blinded to acetaminophen administration.
A multi-center randomized, controlled trial will be the next step in investigating the role of dexmedetomidine and IVA in reducing the incidence of delirium.
F1000Research: Dataset 1. The datasets used and/or analyzed during the current study. No statistical evaluation was done due to the small sample size., 10.5256/f1000research.12552.d18082816
This study has been approved by the Committee on Clinical Investigations at Beth Israel Deaconess Medical Center (IRB Protocol #: 2013-P-000149). Informed consent was obtained for all subjects prior to initiation of study procedures. The study was conducted from 13th November 2013 to 9th April 2015.
The authors declare that they have no competing interests of conflicts of interest.
Balahundhar Subramaniam is supported by the National Institutes of Health Research Project Grant GM 098406.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
No
Competing Interests: No competing interests were disclosed.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||||
---|---|---|---|---|
1 | 2 | 3 | 4 | |
Version 2 (revision) 21 Dec 17 |
read | read | read | read |
Version 1 16 Oct 17 |
read | read |
Click here to access the data.
Spreadsheet data files may not format correctly if your computer is using different default delimiters (symbols used to separate values into separate cells) - a spreadsheet created in one region is sometimes misinterpreted by computers in other regions. You can change the regional settings on your computer so that the spreadsheet can be interpreted correctly.
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)